Plaque Psoriasis: PASI/BSA Severity, Topicals, Phototherapy, IL-17/IL-23 Biologics

Dermatology · Inflammatory Skin Disease

Plaque Psoriasis: Severity Assessment and Stepwise Therapy

Evidence-based guideClinician referenceBy gomdori, MD
Executive Summary

Plaque psoriasis affects 2–3% of the global population and represents the most common phenotype, accounting for 80–90% of psoriasis cases. The disease arises from dysregulated IL-23/IL-17 axis activation in the skin, driving keratinocyte hyperproliferation and the characteristic well-demarcated erythematous plaques with silvery scale on extensor surfaces, scalp, and lumbosacral areas. Severity assessment combines body surface area (BSA), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), and special-site involvement; severe disease is defined as BSA >10%, PASI >10, or DLQI >10 — or any disease at high-impact sites (face, palms/soles, scalp, genitals, nails). Mild localized disease is managed with potent topical corticosteroids (clobetasol propionate 0.05% BID), vitamin D analogues (calcipotriene 0.005% BID), or fixed combinations (calcipotriene/betamethasone). Moderate-to-severe disease unresponsive to topicals or affecting high-impact sites warrants narrowband UVB phototherapy (3× weekly) or systemic therapy. Methotrexate 15–25 mg PO/SC weekly, cyclosporine 2.5–5 mg/kg/day, apremilast 30 mg PO BID, and acitretin 10–50 mg PO daily remain useful conventional systemics; biologics — anti-TNF (adalimumab, etanercept, infliximab, certolizumab), anti-IL-17 (secukinumab, ixekizumab, brodalumab, bimekizumab), anti-IL-23 (risankizumab, guselkumab, tildrakizumab) — and oral JAK/TYK2 inhibitors (deucravacitinib) achieve PASI 90 in 60–80% of patients. Comorbidity screening for psoriatic arthritis (30%), cardiovascular disease, metabolic syndrome, depression/anxiety, and inflammatory bowel disease is mandatory at diagnosis and follow-up.

2–3%
global prevalence
30%
develop psoriatic arthritis
60–80%
PASI 90 with biologics
+1.5×
CV death risk severe disease

1. Pathophysiology & Epidemiology

IL-23/IL-17 Axis Drives Disease

Plaque psoriasis results from a self-perpetuating immune-keratinocyte loop. Dendritic cells in the dermis produce IL-23 in response to undefined triggers (genetic risk loci including HLA-Cw6, IL-23R, IL-12B, ERAP1; environmental triggers — streptococcal pharyngitis, drugs such as lithium and beta-blockers, smoking, alcohol, mechanical trauma producing the Köbner phenomenon). IL-23 maintains and expands Th17 cells, which secrete IL-17A, IL-17F, IL-22, and TNF-α. IL-17A acts on keratinocytes to drive epidermal hyperproliferation (epidermal turnover accelerated from 28 days to 4 days), aberrant differentiation (parakeratotic stratum corneum), and recruitment of neutrophils (Munro microabscesses) and angiogenic factors. The IL-23/IL-17 axis is the central therapeutic target — blocking IL-23 (risankizumab, guselkumab, tildrakizumab) prevents Th17 maintenance, while blocking IL-17A or its receptor (secukinumab, ixekizumab, bimekizumab, brodalumab) directly disrupts effector function.

The Comorbidity Link

Psoriasis is a systemic inflammatory disease, not a cosmetic skin condition. The same IL-23/IL-17/TNF axis driving cutaneous disease promotes endothelial dysfunction, atherosclerosis, insulin resistance, hepatic steatosis, and joint inflammation. Severe psoriasis (BSA >10%) confers approximately 50% increased cardiovascular mortality, and the relative risk of myocardial infarction is increased 1.5–3-fold in young patients with severe disease. Psoriatic arthritis develops in approximately 30% of patients (typically 8–10 years after skin onset, but psoriasis can also follow arthritis) and is now actively screened for at every dermatology visit using brief tools such as PEST or PsAID. Other major associations include obesity (50% of severe psoriasis patients), metabolic syndrome (40%), inflammatory bowel disease (3-fold increased), depression (20% major depressive disorder; suicidal ideation in 10%), uveitis, and non-alcoholic fatty liver disease.

Plaque Psoriasis — Lesion Morphology Skin lesion morphology classification showing 8 lesion types Plaque Psoriasis — Lesion Morphology Macule Flat, <1cm color change Patch Flat, >1cm color change Papule Raised solid, <1cm Plaque Raised flat-topped, >1cm Nodule Solid, 1-2cm deep Vesicle Fluid-filled, <1cm Bulla Fluid-filled, >1cm Pustule Pus-filled
Plaque Psoriasis — Lesion Morphology

2. Severity Assessment

PASI / BSA / DLQI Triangulation

Three complementary metrics define severity:

  • BSA (Body Surface Area): Patient palm = 1% BSA. <3% mild, 3–10% moderate, >10% severe.
  • PASI (Psoriasis Area and Severity Index): Combines erythema, induration, scale (each 0–4) with body region area (head 10%, upper limbs 20%, trunk 30%, lower limbs 40%). Range 0–72. <5 mild, 5–10 moderate, >10 severe. Treatment goal is PASI 90 (90% improvement) with PASI 100 increasingly achievable.
  • DLQI (Dermatology Life Quality Index): 10-question patient-reported quality-of-life instrument. 0–1 no impact, 2–5 small effect, 6–10 moderate, 11–20 very large effect, 21–30 extremely large effect. DLQI >10 indicates severe quality-of-life impairment regardless of BSA.

Severe disease is defined when any one of BSA >10%, PASI >10, or DLQI >10 is present — the "rule of tens" — and warrants systemic therapy. The IPC (International Psoriasis Council) updated definition in 2020 broadened this to include high-impact sites (scalp, palms/soles, face, genitals, nails) regardless of overall BSA.

Special-Site Disease Modifies Severity

Even small BSA at certain anatomic sites profoundly impairs quality of life and warrants escalation to systemic therapy:

SiteClinical impactTreatment considerations
Scalp50% of patients; severe pruritus, embarrassment, hair lossClobetasol propionate 0.05% solution/foam BID; calcipotriene/betamethasone gel; tar shampoos; biologics if severe
Face/intertriginousHighly visible; thin skin limits steroid potencyMid-potency steroid (triamcinolone 0.1%) short course; tacrolimus 0.1% ointment BID or pimecrolimus 1% BID; calcipotriene cautiously
Palms/solesDisabling — limits work, walking; resistant to topicalsAcitretin 25–35 mg PO daily; hand-foot UVB; biologics (IL-17 strongly effective); guselkumab approved
NailsPitting, onycholysis, oil drop sign; predictor of psoriatic arthritisTopicals minimally effective; intralesional triamcinolone 2.5–5 mg/mL; biologics — IL-17 and IL-23 inhibitors significantly improve NAPSI
Genitals30% of patients; severe sexual dysfunction and DLQI impactMid-potency topical short course; tacrolimus 0.1% ointment; ixekizumab and risankizumab have specific genital psoriasis trials
PASI score componentsSchematic showing 4 body regions (head, upper limbs, trunk, lower limbs), area weights (0.1, 0.2, 0.3, 0.4), and severity components (erythema, induration, scale each 0-4). PASI = Σ (Region weight × Area score × [Erythema + Induration + Scale]) REGION WEIGHTS Head/neck× 0.1 Upper limbs× 0.2 Trunk× 0.3 Lower limbs× 0.4 Total = 1.0 AREA SCORE (0–6) 0 = no involvement 1 = <10% 2 = 10–<30% 3 = 30–<50% 4 = 50–<70% 5 = 70–<90% 6 = 90–100% SEVERITY (each 0–4) Erythema: 0–4 0=none, 4=very severe red Induration: 0–4 0=none, 4=>1.25 mm thick Scale: 0–4 0=none, 4=very thick scale

3. Diagnosis & Workup

Plaque psoriasis is a clinical diagnosis based on characteristic morphology — well-demarcated erythematous plaques with silvery-white micaceous scale on extensor surfaces (elbows, knees), scalp, lumbosacral area, umbilicus, and gluteal cleft. The Auspitz sign (pinpoint bleeding on scale removal) reflects the elongated dermal papillae and is supportive but non-specific. The Köbner phenomenon — new plaques developing in lines of trauma — is characteristic. Scratch test (gentle scraping reveals coherent silvery scale, then "membrane" of Bulkeley, then Auspitz pinpoint bleeding) confirms the diagnosis at the bedside.

Differential Diagnosis

ConditionDistinguishing feature
Atopic dermatitisFlexural distribution, more pruritic, ill-defined edges, lichenification, high IgE
Seborrheic dermatitisYellow greasy scale on scalp, eyebrows, nasolabial folds; sebum-rich areas; less induration
Lichen planusPruritic violaceous flat-topped papules; Wickham striae; mucosal involvement
Tinea corporisAnnular with central clearing; KOH shows hyphae
Mycosis fungoidesPersistent patches/plaques in non-sun-exposed areas; skin biopsy with TCR clonality
Pityriasis roseaAcute herald patch, Christmas-tree distribution on trunk; self-limited 6–8 weeks
Subacute cutaneous lupusPhotosensitive distribution; positive Ro/SSA; biopsy with interface dermatitis
Discoid eczemaCoin-shaped pruritic plaques; weeping/crusting; less induration

Workup at Diagnosis & Pre-Biologic

  • Skin biopsy: Reserved for atypical presentations or to exclude CTCL — shows confluent parakeratosis, regular acanthosis with thinned suprapapillary plates, dilated papillary capillaries, Munro microabscesses, and absent granular layer
  • Comorbidity screen at every visit: Joint pain (PEST or PsAID instrument for PsA screening), BP, BMI, waist circumference, depression screen (PHQ-2)
  • Baseline labs (pre-systemic/biologic): CBC, comprehensive metabolic panel, LFTs, lipid panel, fasting glucose or HbA1c, hepatitis B (HBsAg, HBcAb, HBsAb), hepatitis C (HCV Ab), HIV, latent TB testing (IGRA preferred over PPD), pregnancy test in women of childbearing age
  • Pre-methotrexate: Baseline CBC, LFTs, creatinine, hepatitis B/C, pregnancy test; chest X-ray if pulmonary risk
  • Pre-cyclosporine: Baseline BP (must be controlled), creatinine ×2, magnesium, uric acid, lipids, CBC
  • Pre-anti-IL-17: Latent TB; consider IBD screening — anti-IL-17 may worsen IBD
  • Pre-anti-TNF: Latent TB; HBV serology mandatory; HF screening (avoid in NYHA III–IV); demyelinating disease history
  • Pre-JAK/TYK2 inhibitors (deucravacitinib): Baseline lipid panel, CBC; lipid monitoring on therapy
PsA screening at every visit30% of psoriasis patients develop psoriatic arthritis. Use the PEST (5-item Psoriasis Epidemiology Screening Tool) or PsAID at every dermatology visit; ≥3 positive items warrants rheumatology referral. Early PsA diagnosis and treatment prevents irreversible joint erosion. The presence of nail involvement, scalp psoriasis, or intergluteal psoriasis carries the highest PsA risk.
Plaque Psoriasis — Procedure Steps Surgical stepper: Plaque Psoriasis — Procedure Steps Plaque Psoriasis — Procedure Steps 1 Topicals (mild) High-potency steroids (clobetasol 0.05%) + vitamin D analog (calcipotriene); intermittent 2 Phototherapy NB-UVB 2-3×/week × 12-24 weeks for moderate; effective + safe 3 Conventional systemics Methotrexate 15-25 mg/week + folic acid; cyclosporine; acitretin (less effective) 4 Biologics — IL-17 Secukinumab 300mg q4wk OR ixekizumab 80mg q4wk OR brodalumab; PASI 90 in 70-80% 5 Biologics — IL-23 Risankizumab 150mg q12wk OR guselkumab 100mg q8wk OR tildrakizumab; PASI 90 in 70-80% 6 Biologics — anti-TNF / IL-12/23 Adalimumab, etanercept, infliximab; ustekinumab (IL-12/23); for PsA + skin
Plaque Psoriasis — Procedure Steps

4. Stepwise Therapy

Step 1 — Mild Disease: Topical & Phototherapy

ClassExamples and dosingDuration/limits
Topical corticosteroidsClobetasol propionate 0.05% cream/ointment BID × 2 weeks (super-potent); triamcinolone 0.1% BID (mid-potency); hydrocortisone 1% for face/foldsLimit super-potent to 2-week courses; 50 g/week max; taper to weekend pulse maintenance
Vitamin D analoguesCalcipotriene 0.005% cream/ointment BID; calcitriol 0.003% BIDSteroid-sparing; max 100 g/week to avoid hypercalcemia; safe long-term
Fixed combinationsCalcipotriene/betamethasone foam, gel, ointment, suspension QDMost effective topical class; PASI 75 in 30–50%; QD dosing improves adherence
Topical calcineurin inhibitorsTacrolimus 0.1% ointment BID; pimecrolimus 1% cream BIDOff-label; preferred for face, intertrigine, genital — no skin atrophy
Coal tar/anthralinTar 2–10% shampoo, ointment; short-contact anthralin (15–30 min)Adjunct; messy, smelly; effective for thick chronic plaques
Topical retinoidsTazarotene 0.1% cream/gel HSIrritating; combine with topical steroid; reduce frequency for tolerance
Roflumilast cream 0.3%QD (PDE4 inhibitor — newer)Approved 2022; effective intertriginous and chronic plaque
Tapinarof cream 1%QD (aryl hydrocarbon receptor agonist)Approved 2022; non-steroidal; effective; possible folliculitis

Phototherapy

Narrowband UVB (311–313 nm) 3× weekly × 12 weeks is the most studied phototherapy modality and achieves PASI 75 in 60–70% of patients. Targeted excimer laser (308 nm) treats limited plaques. PUVA (psoralen + UVA) is more effective but has fallen from favor due to skin cancer risk with cumulative exposure (>200 sessions or >1500 J/cm² associated with squamous cell carcinoma). Home NB-UVB units improve adherence in patients with transportation barriers. Phototherapy combined with topical vitamin D analogues, methotrexate, or biologics enhances response.

Step 2 — Moderate-Severe: Conventional Systemic

AgentStandard doseKey monitoring
Methotrexate15–25 mg PO/SC weekly + folic acid 1 mg PO dailyCBC, LFTs, creatinine q4 weeks initially then q2–3 months; cumulative dose >1.5 g consider FibroScan
Cyclosporine2.5–5 mg/kg/day PO divided BID × ≤6 monthsBP and creatinine q2 weeks initially then monthly; nephrotoxicity is dose- and time-dependent; avoid live vaccines
Acitretin10–50 mg PO dailyLFTs, lipids q3 months; iPledge-like teratogen counseling — pregnancy contraindicated for 3 years post-discontinuation
Apremilast (oral PDE4)30 mg PO BID after 5-day titrationWeight loss, depression — screen at baseline and ongoing; nausea/diarrhea common first month
Deucravacitinib (oral TYK2)6 mg PO dailyLipid panel q3 months; CBC; oral non-biologic; superior to apremilast in PASI 75 response

Step 3 — Biologic Therapy

Class & agentStandard dosePASI 90 at 16 wks
Anti-TNF: Adalimumab80 mg SC week 0, 40 mg week 1, then 40 mg q2 wks~45%
Anti-TNF: Etanercept50 mg SC twice weekly × 12 wks then weekly~35%
Anti-TNF: Infliximab5 mg/kg IV at wks 0/2/6 then q8 wks~55%
Anti-IL-12/23: Ustekinumab45 mg (≤100 kg) or 90 mg SC at wks 0, 4 then q12 wks~50%
Anti-IL-17A: Secukinumab300 mg SC wks 0, 1, 2, 3, 4 then q4 wks~70%
Anti-IL-17A: Ixekizumab160 mg SC wk 0, 80 mg wks 2/4/6/8/10/12 then 80 mg q4 wks~75%
Anti-IL-17R: Brodalumab210 mg SC wks 0, 1, 2 then q2 wks~70% (boxed warning suicidal ideation)
Anti-IL-17A/F: Bimekizumab320 mg SC q4 wks × 16 wks then q8 wks~85% (highest)
Anti-IL-23 p19: Risankizumab150 mg SC wks 0, 4 then q12 wks~75%
Anti-IL-23 p19: Guselkumab100 mg SC wks 0, 4 then q8 wks~70%
Anti-IL-23 p19: Tildrakizumab100 mg SC wks 0, 4 then q12 wks~60%

Selecting Among Biologics

For most adults with moderate-to-severe plaque psoriasis without contraindications, IL-23 inhibitors (risankizumab, guselkumab) and IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab) provide the highest skin clearance with excellent safety. Anti-IL-23 agents offer the longest dosing intervals (q8–12 weeks maintenance) — best for patient adherence. Select anti-TNF (adalimumab, infliximab) when concurrent psoriatic arthritis or inflammatory bowel disease drives therapy, as IL-17 inhibitors can paradoxically worsen IBD. Avoid IL-17 inhibitors in patients with active or recent IBD; avoid anti-TNF in NYHA III–IV heart failure or active demyelinating disease. Consider patient preference for injection schedule, comorbidities, and insurance coverage.

Plaque psoriasis treatment algorithmStepped algorithm from mild disease through moderate to severe with topical, phototherapy, conventional systemic, and biologic interventions. Plaque psoriasis: severity → treatment match MILD (BSA <3, PASI <5, DLQI ≤5)• Clobetasol 0.05% BID• Calcipotriene/beta combo• Roflumilast / tapinarof MODERATE (BSA 3–10, PASI 5–10)• NB-UVB 3×/week• Methotrexate 15–25 mg/wk• Apremilast / Deucravacitinib SEVERE (BSA >10, PASI >10, DLQI >10)• Anti-IL-23 (risankizumab)• Anti-IL-17 (bimekizumab)• Anti-TNF if PsA/IBD SPECIAL SITES (any BSA): treat as severe regardless of overall extentScalp · Face · Palms/soles · Nails · Genitals → escalate to systemic/biologic Treatment goal: PASI 90 within 16 weeks; lifestyle modification (weight loss, smoking cessation) at every visit

5. Special Populations & Referral

PopulationAdjustment
PregnancyTopical corticosteroids (mild-moderate potency, <200 g/month) and emollients are first-line; NB-UVB safe; certolizumab pegol preferred biologic (no Fc; doesn't cross placenta); avoid methotrexate, acitretin, cyclosporine, JAK inhibitors
Pediatric (≥6 yr)Topicals; NB-UVB; ustekinumab, etanercept, ixekizumab, secukinumab, adalimumab, risankizumab approved; avoid acitretin (skeletal toxicity), methotrexate cautious
Active HBV or HCVAnti-TNF requires antiviral co-treatment (entecavir 0.5 mg PO daily for HBV); IL-17 and IL-23 inhibitors may be safer in HCV; coordinate with hepatology
Latent TB (positive IGRA)INH 300 mg PO daily × 9 months or rifampin 600 mg PO daily × 4 months before biologic; can start biologic 1–2 months after INH initiated
Active or recent IBDAvoid IL-17 inhibitors (paradoxical IBD flares); favor anti-TNF (also treats IBD), risankizumab, guselkumab, ustekinumab
Heart failure NYHA III–IVAvoid anti-TNF (worsens HF); IL-17, IL-23 inhibitors safe
History of demyelinating diseaseAvoid anti-TNF; favor IL-17 or IL-23 inhibitors
Active malignancy or recent treatmentAvoid biologics in active hematologic/skin malignancy; consult oncology; topicals + NB-UVB
Erythrodermic or generalized pustular psoriasisHospitalize; cyclosporine 3–5 mg/kg/day rapid onset; spesolimab (anti-IL-36R) 900 mg IV ×1 for generalized pustular flare; avoid systemic steroids (rebound flare)
When to refer urgentlyErythrodermic psoriasis (≥90% BSA) or generalized pustular psoriasis (von Zumbusch) is a dermatologic emergency requiring same-day referral and frequently inpatient admission for fluid management, temperature regulation, infection prophylaxis, and rapid-onset systemic therapy. New onset of joint pain, dactylitis, or enthesitis warrants rheumatology referral within 4 weeks for psoriatic arthritis evaluation. Suicidal ideation or severe depression requires immediate mental health referral. Suspected cardiovascular event in a young patient with severe psoriasis requires urgent cardiology evaluation given the elevated baseline risk.

Long-Term Surveillance & Comorbidity Management

Cardiovascular risk modification is the most under-recognized intervention in psoriasis care. At every visit: BP, BMI, waist circumference, smoking status, depression screen. Annually: lipid panel, fasting glucose or HbA1c, cardiovascular risk calculator (e.g., ASCVD risk score). Statin therapy at lower thresholds for severe psoriasis given the inflammation-driven cardiovascular risk multiplier. Weight loss to BMI <25 substantially improves psoriasis severity and biologic response (each 5% weight loss adds approximately 25% improvement in topical-treated patients). Smoking cessation counseling at every visit. Mediterranean diet associated with reduced PASI in observational studies. Annual depression screening with PHQ-2/PHQ-9. Skin cancer surveillance for patients on cyclosporine, biologics, or with prior PUVA. Vaccination updates (PCV20, RSV, recombinant zoster, annual influenza) with planning before biologics — live vaccines contraindicated on biologics or methotrexate.

6. Pearls, Pitfalls & FAQ

Pearl — The "rule of tens" launches systemic therapyBSA >10%, PASI >10, or DLQI >10 — any one of these defines severe disease deserving systemic therapy. Do not wait for all three. A patient with BSA 4% but DLQI 18 due to genital and palmar involvement has severe disease by impact and warrants escalation past topicals.
Pitfall — Systemic corticosteroids in psoriasisSystemic prednisone causes rebound flare upon withdrawal — sometimes converting stable plaque disease into erythrodermic or generalized pustular psoriasis. Never use systemic steroids for psoriasis except as last resort (e.g., rapid bridge to cyclosporine in pregnancy-related erythrodermic flare). Topical steroids are fine; systemic is not.
Pearl — Screen for PsA at every visit, not annually30% of psoriasis patients develop psoriatic arthritis. Brief screening tools (PEST: 5 yes/no questions) take under 90 seconds and detect early disease before joint erosion is established. Nail pitting, scalp involvement, and intergluteal psoriasis confer the highest risk and warrant the lowest threshold for rheumatology referral.
Pitfall — Choosing IL-17 inhibitor in undiagnosed IBDAnti-IL-17 agents (secukinumab, ixekizumab, brodalumab, bimekizumab) can unmask or exacerbate inflammatory bowel disease. A targeted history for chronic diarrhea, blood in stool, weight loss, abdominal pain, or family history of IBD is mandatory before initiating IL-17 therapy. When IBD risk exists, choose anti-IL-23 (risankizumab, guselkumab) or anti-TNF instead.
When should I move from topical therapy to systemic or biologic therapy?

Move to systemic or biologic therapy when any of the following apply: BSA >10%, PASI >10, or DLQI >10 (the "rule of tens"); special-site involvement (face, palms/soles, scalp, nails, genitals) regardless of overall BSA; failure of optimized topical therapy after 8–12 weeks; concurrent psoriatic arthritis; or inability to apply topicals due to physical limitations. The 2020 IPC consensus broadened severe-disease definition to include high-impact sites alongside traditional severity metrics. Biologics are now first-line for moderate-severe disease in most international guidelines, displacing methotrexate as initial systemic in many settings — particularly given superior PASI 90 rates (60–85% with modern biologics versus 20–30% with methotrexate alone) and better long-term safety profile.

How do IL-17 and IL-23 inhibitors differ in clinical use?

Both target the IL-23/Th17 axis but at different levels. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) block the downstream effector cytokine and produce rapid skin clearance — most patients achieve PASI 75 by week 4. IL-23 inhibitors (risankizumab, guselkumab, tildrakizumab) block the upstream cytokine that maintains pathogenic Th17 cells — onset is somewhat slower (PASI 75 by week 12) but maintenance is excellent with q8–12-week dosing. Bimekizumab (dual IL-17A/F) achieves the highest PASI 90 rates (~85%) at 16 weeks. For concurrent psoriatic arthritis, both classes are effective, with IL-17 inhibitors having strong axial spondyloarthritis evidence. Avoid IL-17 inhibitors in active or recent IBD — they can paradoxically worsen IBD; favor IL-23 inhibitors or anti-TNF in this setting. For convenience, IL-23 inhibitors win with q8–12-week maintenance dosing.

What is the role of deucravacitinib and the new oral agents?

Deucravacitinib is an oral allosteric TYK2 inhibitor approved 2022 for moderate-to-severe plaque psoriasis at 6 mg PO daily. It selectively inhibits TYK2 (one of the JAK family) without significant inhibition of JAK1/2/3, distinguishing it from broader JAK inhibitors like tofacitinib. PASI 75 response at week 16 is approximately 55–60%, superior to apremilast and approaching some biologics. Major advantages: oral administration, once-daily dosing, no laboratory monitoring schedule beyond baseline (lipids checked at baseline and periodically), and no boxed warning — distinguishing it from JAK inhibitors. Apremilast (PDE4 inhibitor, 30 mg PO BID) remains useful for milder disease, scalp involvement, or patients preferring oral therapy with established long-term safety. These oral agents fill an important niche between topical/conventional and biologics for patients averse to injections.

How should I screen and manage cardiovascular risk in psoriasis patients?

Severe psoriasis confers approximately 50% increased cardiovascular mortality and 2–3-fold increased myocardial infarction risk in young patients — the inflammation-driven cardiovascular risk parallels rheumatoid arthritis. Screen at every visit: blood pressure, BMI, waist circumference, smoking status. Annually: fasting lipid panel, fasting glucose or HbA1c, ASCVD risk calculator. The 2018 American Academy of Dermatology / National Psoriasis Foundation guidelines recommend lower statin thresholds for severe psoriasis given the inflammation multiplier. Aggressively manage all traditional risk factors. Weight loss to BMI <25 reduces psoriasis severity and improves biologic response. Smoking cessation is critical. Mediterranean diet may reduce PASI in observational studies. Effective treatment of skin disease with biologics may itself reduce cardiovascular events, though randomized cardiovascular outcome trials are still emerging.

What is generalized pustular psoriasis and how is it managed differently?

Generalized pustular psoriasis (GPP, von Zumbusch type) is a severe, often life-threatening psoriasis variant characterized by sudden widespread eruption of sterile pustules on erythematous skin accompanied by fever, leukocytosis, hypocalcemia, and elevated inflammatory markers. It can be precipitated by withdrawal of systemic corticosteroids, infection, pregnancy (impetigo herpetiformis), or hypocalcemia. IL36RN, CARD14, and AP1S3 mutations account for some familial cases. Treatment is hospital-based: fluid and electrolyte management; spesolimab (anti-IL-36R monoclonal) 900 mg IV ×1 is the only FDA-approved therapy for acute GPP flare and produces rapid clearance within 1 week; cyclosporine 3–5 mg/kg/day for rapid onset; infliximab 5 mg/kg IV at weeks 0/2/6 for non-spesolimab-responsive cases. Long-term prevention with biologics — risankizumab and bimekizumab also have GPP indications. Avoid systemic corticosteroids (rebound risk).

S7. Practice Insights: Plaque Psoriasis Modern Biologic Era

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Body surface area gets estimated in seconds while the patient explains he has stopped swimming and stopped wearing short sleeves, and in plaque psoriasis the dominant management failures are: keeping moderate-to-severe disease on topicals indefinitely when systemic biologic therapy would have transformed the patient's life, choosing IL-17 vs IL-23 biologics by formulary rather than clinical phenotype (each has distinct strengths), missing the systematic comorbidity screening (psoriatic arthritis, cardiovascular disease, IBD, depression) that should be part of every visit, and undertreating psoriasis as a cosmetic condition when the disability and comorbidity burden are substantial. In experienced practice, four operational principles guide modern psoriasis care.

1. PASI/BSA Severity Stratification

In practice, severity drives the entire therapeutic ladder. Mild psoriasis (BSA <5% AND PASI <5) is appropriate for topical therapy alone. Moderate disease (BSA 5-10% OR PASI 5-10 OR DLQI >10 reflecting significant QoL impact even with limited BSA) qualifies for phototherapy or systemic therapy. Severe disease (BSA >10% OR PASI >10 OR involvement of face/genitals/palms/soles regardless of BSA) warrants systemic biologic therapy. The "rule of tens" simplification: BSA >10 OR PASI >10 OR DLQI >10 indicates systemic therapy is appropriate. The QoL adjustment matters because limited body surface area but significant face/genital/hand involvement is functionally severe even when BSA is <5%.

2. Topical First-Line for Mild Disease

For mild plaque psoriasis, in experienced hands the first-line is combination topical corticosteroid plus vitamin D3 analog: calcipotriene-betamethasone (Enstilar foam, Taclonex ointment/suspension) once daily for 4 weeks then 2-3x weekly maintenance. The combination is superior to either monotherapy and reduces steroid skin atrophy risk by lowering total steroid exposure. For face/skin folds: low-potency topical steroid (hydrocortisone 1%) plus calcineurin inhibitor (tacrolimus 0.1% ointment or pimecrolimus 1% cream) avoiding steroid atrophy. Tazarotene gel/cream is an alternative non-steroid topical. Coal tar preparations are historic and have specific niches but have largely been superseded. Topical therapy alone for moderate-severe disease is the dominant undertreatment pattern.

3. IL-17 vs IL-23 Biologic Selection

For moderate-severe disease in practice, biologic selection follows clinical phenotype. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) have faster onset (peak skin clearance ~12-16 weeks) and broader efficacy in psoriatic arthritis, ankylosing spondylitis, and pustular psoriasis. They have a small but real signal for Candida infections and IBD reactivation (avoid in patients with concurrent active IBD). IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) have slower onset but excellent long-term retention rates and durable response with less frequent dosing (typically every 8-12 weeks); preferred in patients without inflammatory arthritis priority and where simpler maintenance schedule matters. TNF inhibitors (adalimumab, etanercept, infliximab) remain useful particularly when psoriatic arthritis is primary or when biosimilar cost considerations matter, but they have been largely replaced by IL-17/IL-23 inhibitors for skin priority.

4. Comorbidity Screening at Every Visit

Psoriasis is a systemic inflammatory disease with well-documented comorbidities. In practice, every psoriasis visit includes structured screening: psoriatic arthritis screen (PEST questionnaire: joint pain, swelling, dactylitis, enthesitis, nail pitting — approximately 30% of psoriasis patients develop PsA), cardiovascular risk assessment (lipid panel, blood pressure, weight, smoking status — psoriasis is an independent CV risk factor approximately equivalent to diabetes), metabolic screening (HbA1c if BMI >25 or family history), depression/anxiety screen (PHQ-2 or PHQ-9), IBD screening if any GI symptoms (Crohn-psoriasis genetic overlap), liver function (NAFLD/MASLD increased in psoriasis). Documented PsA changes management toward IL-17 or TNF inhibitor preferentially. Documented CV risk drives statin and lifestyle counseling. This integrated screening is the difference between treating "skin disease" and treating systemic inflammatory disease.

Illustrative Scenario: Biologic-Transformed Severe Psoriasis

A man in his early 40s with 15-year history of plaque psoriasis presented after years of topical therapy alone for BSA 22% involvement, PASI 18, DLQI 24 (severely impaired quality of life). He had not been offered biologic therapy by his previous dermatologist who "preferred to avoid systemic medication." He had been employed in a sales role but had transitioned to remote-only work because of plaque embarrassment in client meetings, and was struggling with depression. PEST questionnaire was positive (joint pain, dactylitis of one finger), confirming concurrent psoriatic arthritis.

Workup: HbA1c 6.4%, BMI 31, total cholesterol 245, family history of MI before 60 in father. Documented metabolic syndrome and CV risk factors in addition to skin disease. The treating clinicians started ixekizumab (IL-17 inhibitor, given concurrent PsA) at standard induction dose. By week 12 he had PASI 75 response (75% improvement); by week 24 he was at PASI 90 with near-complete skin clearance. The PsA joint symptoms also resolved. He started a statin for CV risk modification, lost 8 kg with structured lifestyle intervention, and engaged in CBT for the depression that had developed over years of untreated disease. He returned to full in-person work and described the transformation as "life-changing."

Takeaway: Moderate-severe plaque psoriasis is not a cosmetic condition. Biologic therapy has transformed quality of life and reduced systemic inflammation. Patients with PASI >10, BSA >10%, or DLQI >10 deserve systemic therapy options. PsA + skin priority favors IL-17 inhibitor. Concurrent CV/metabolic/mood screening matters.

Practice Pattern Refinements vs Standard Approach

  • Severity stratification: rule of tens (BSA OR PASI OR DLQI >10) = systemic therapy. QoL adjustment for face/genital/hand involvement.
  • Topical combo first-line for mild: calcipotriene-betamethasone foam/ointment daily x 4 wk then maintenance. Calcineurin inhibitor for face/folds. Topical alone undertreats moderate-severe.
  • IL-17 vs IL-23 by phenotype: IL-17 for PsA / fast onset / pustular; IL-23 for skin priority / durable maintenance. Avoid IL-17 in active IBD.
  • Comorbidity screening every visit: PEST for PsA, CV risk, metabolic, depression, IBD if GI sx. Psoriasis is systemic inflammatory disease, not cosmetic.
Plaque Psoriasis: 4-Pillar Modern Framework Four-panel framework: PASI/BSA severity, topical first-line, IL-17 vs IL-23, comorbidity screening. Plaque Psoriasis: 4-Pillar Modern Framework 1. Severity Stratification (Rule of 10s) Mild: BSA < 5% + PASI < 5 Topical therapy alone Moderate: BSA 5-10 or PASI 5-10 Phototherapy or systemic Severe: BSA > 10 OR PASI > 10 Systemic biologic DLQI > 10 = severe regardless of BSA Face/genitals/hands functionally severe 2. Topical First-Line (Mild) Calcipotriene-betamethasone Daily × 4 wk → 2-3x/wk maintenance Face/folds: hydrocortisone + tacrolimus Avoid steroid atrophy Topical alone for moderate-severe = dominant undertreatment pattern Refer to derm for systemic if eligible 3. IL-17 vs IL-23 by Phenotype IL-17 inhibitor Secukinumab/ixekizumab Brodalumab/bimekizumab Faster onset, PsA priority Avoid in active IBD IL-23 inhibitor Guselkumab/risankizumab Tildrakizumab Durable maintenance q8-12 wk dosing TNF (adalimumab) for biosimilar cost Or when PsA primary priority 4. Comorbidity Screening PEST for PsA (~30% develop) CV risk (lipids, BP, weight, smoking) HbA1c if BMI > 25 or FHx PHQ-2/PHQ-9 depression IBD if GI symptoms LFTs (NAFLD/MASLD) Systemic disease, not cosmetic

Leave a Reply

Your email address will not be published. Required fields are marked *